Format

Send to

Choose Destination
See comment in PubMed Commons below
Ann Dermatol. 2016 Aug;28(4):444-50. doi: 10.5021/ad.2016.28.4.444. Epub 2016 Jul 26.

Safety and Tolerability of the Dual 5-Alpha Reductase Inhibitor Dutasteride in the Treatment of Androgenetic Alopecia.

Author information

  • 1Department of Dermatology, Inha University College of Medicine, Incheon, Korea.
  • 2GlaxoSmithKline, Seoul, Korea.
  • 3Department of Dermatology and Institute of Hair & Cosmetic Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea.

Abstract

BACKGROUND:

After the approval of dutastride for androgenic alopecia (AGA) in 2009, Korean authority required a post-marketing surveillance to obtain further data on its safety profile.

OBJECTIVE:

The objective was to monitor adverse events (AEs) of dutasteride 0.5 mg in Korean AGA male patients in a clinical practice environment.

METHODS:

Open label, multi-center, non-interventional observational study was done from July 2009 to July 2013. AGA subjects (18~41 years of age) with no experience of dutasteride were enrolled. Dosage regimen was recommended according to the prescribing information. The incidences of any AEs, serious adverse events (SAEs), and adverse drug reactions (ADRs) were evaluated. Multiple logistic regression method was used to identify risk factors related to ADRs. Effectiveness was generally evaluated by physicians.

RESULTS:

During study period, 712 subjects were enrolled. The subjects of 29.3±6.0 years old exposed to dutasteride for 204.7±161.5 days. One hundred and ten (15.4%) of subjects reported 138 AEs. Four subjects (0.6%) reported 5 SAEs (right radius fracture, 2 events of chronic follicular tonsillitis, influenza infection, and acute appendicitis). Sixty-six subjects (9.3%) reported 80 ADRs. Most frequent ADRs were libido decreased (9 subjects, 1.3%), dyspepsia (8 subjects, 1.1%), impotence (7 subjects, 1.0%), and fatigue (5 subjects, 0.7%). Other interested ADRs were sexual function abnormality (4 subjects, 0.6%), gynecomastia (2 subjects, 0.3%), and ejaculation disorder (1 subject, 0.1%). Most subjects (78.6%) showed overall improvement after treatment of dutasteride in the effectiveness.

CONCLUSION:

Dutasteride 0.5 mg is to be well-tolerated in 18 to 41 years old AGA patients in a clinical practice environment.

KEYWORDS:

Alopecia; Drug-related side effects and adverse reactions; Dutasteride; Product surveillance; Safety; Treatment outcome; postmarketing

PMID:
27489426
PMCID:
PMC4969473
DOI:
10.5021/ad.2016.28.4.444
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Korean Dermatological Association Icon for PubMed Central
    Loading ...
    Support Center